AMD diagnostic imaging
Patients are unaware they have a ticking time bomb in their eyes
Sean Henahan
Published: Tuesday, March 28, 2017
Patients are unaware they have a ticking time bomb in their eyesICG angiography Why not use ICG angiography to follow patients? That approach is expensive, invasive, time consuming, resource intensive, and until recently, such cases didn't have an intervention, he noted. Rather, Dr Rosenfeld and colleagues used a novel swept source OCT angiography system to look for subclinical CNV. The prototype from Carl Zeiss Meditec performed a 3mm X 3mm rraster scan centered on the fovea and repeated each B-scan 4 times, with 300 A-scans per B-scan, and 300 B-scan positions, for a total of 360,000 A-scans. Using a special decorrelation algorithms, the B-scans were compiled to provide en face flow images of the retina and choroid. The optical microangiographic approach known as OMAG provided provided the microvascular flow information and different layers were segmented, which included the whole retina, the inner or superficial retina layer or plexus, the middle or deep retinal plexus, and the outer avascular retinal layer. Another layer from the outer retinal layer to the choriocapillaris, known as the ORCC layer, was also created since this is where most of the choroidal neovascularization can be found. Subsequent clinical research (Ophthalmology, Roisman et al, Volume 123, Issue 6, 1309–1319) confirmed that the system could detect CNV lesions before they started leaking. Subsequent follow-up of 103 patients with wet AMD in one eye and dry AMD in the other revealed a prevalence of about 18% for these subclinical lesions, with an estimated rate of conversion to exudation of about 16% at one year, but longer follow-up is underway. “This is a new stage of non-exudative AMD. We call it non-exudative neovascular AMD. I think we can find these patients easily with SS-OCTA and we need to follow them closely. Ongoing studies are looking at prevalence, incidence, and onset of exudation. For now, in addition to close follow-up, we do not recommend anti-VEGF treatment,” he concluded. “I never treat asymptomatic patients. I educate my patients, I emphasize the need for vision monitoring at home, and I enlist them to be stewards of their own vision. In addition, if we start treatment in the absence of fluid, what’s our endpoint?,” Rosenfeld stated. prosenfeld@med.miami.edu
Latest Articles
Glaucoma Treatment Under Pressure
New techniques and technologies add to surgeons’ difficult decisions
Outside the Box, Inside the Pipeline
Researchers are tackling glaucoma diagnosis and treatment from all sides.
The EHDS Is Ready for the Green Light
If proposal is approved, Europe could see better access to, and exchange and use of, health data.
ESCRS to Release Guidelines for Cataract and Refractive Surgery
Comprehensive approach to the safest and most effective modern surgery.
Barry Fellowship Opens Up ‘Whole New Field of Thought’
The 2022 recipient combines theoretical and practical to learn new treatments.
Digitalising the OR—Experience and Perspectives
Benefits include saving time and improving outcomes.
Dynamic Measures Needed for Quality of Vision
Functional visual acuity testing and straylight metering may better reflect real-world conditions.
What Is Stopping Digital OR Adoption?
Ophthalmologists know the benefits—now it’s time to construct the right plan.
Time to Move Beyond Monofocal IOLs?
European surgeons appear hesitant to first offer other presbyopia-correcting options to patients.